New combo pills for blood pressure and diabetes pass early safety check
NCT ID NCT07598968
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested two experimental oral drugs, HL1113-R1 and HL1113-R2, in 35 healthy adults to see if they are safe and how the body processes them. The drugs are being developed for high blood pressure and type 2 diabetes. Participants took the drugs alone and together in a crossover design. Since this is a Phase 1 study in healthy people, it does not prove the drugs work for these conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HL1113-R1 and HL1113-R2 (oral drugs for hypertension and type 2 diabetes)
What this could lead to
If successful, this could help develop safer or more effective combination treatments for high blood pressure and type 2 diabetes.
What could go wrong
This is an early Phase 1 trial in healthy people, not patients. It only measures safety and drug levels, not whether the drugs actually work for the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Hospital
Seoul, South Korea